Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9)

Tadahiko Igarashi; Michinori Ogura; Kuniaki Itoh; Masafumi Taniwaki; Kiyoshi Ando; Yoshiaki Kuroda; Kazuhito Yamamoto; Naokuni Uike; Akihiro Tomita; Hirokazu Nagai; Mitsutoshi Kurosawa; Shigeo Mori; Shigeru Nawano; Takashi Terauchi; Yasuo Ohashi; Kensei Tobinai

doi:10.1007/s12185-016-2155-3

Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9)

Tadahiko Igarashi, Michinori Ogura, Kuniaki Itoh, Masafumi Taniwaki, Kiyoshi Ando, Yoshiaki Kuroda, Kazuhito Yamamoto, Naokuni Uike, Akihiro Tomita, Hirokazu Nagai, Mitsutoshi Kurosawa, Shigeo Mori, Shigeru Nawano, Takashi Terauchi, Yasuo Ohashi, Kensei Tobinai

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The authors would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The Clinical trial number should be “UMIN000001603” at the end of Abstract and in the last sentence of the paragraph heading “Study design and patients” under “Materials and methods” section. Secondly, the Fig. 1 was incorrectly published with the meaningless red font. The corrected figure is given below: (Figure presented.).

Original language	English
Pages (from-to)	109-110
Number of pages	2
Journal	International Journal of Hematology
Volume	105
Issue number	1
DOIs	https://doi.org/10.1007/s12185-016-2155-3
Publication status	Published - 01-01-2017
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hematology

Access to Document

10.1007/s12185-016-2155-3

Fingerprint

Dive into the research topics of 'Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9)'. Together they form a unique fingerprint.

Cite this

Igarashi, T., Ogura, M., Itoh, K., Taniwaki, M., Ando, K., Kuroda, Y., Yamamoto, K., Uike, N., Tomita, A., Nagai, H., Kurosawa, M., Mori, S., Nawano, S., Terauchi, T., Ohashi, Y., & Tobinai, K. (2017). Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9). International Journal of Hematology, 105(1), 109-110. https://doi.org/10.1007/s12185-016-2155-3

@article{17c90acde36e44e3b206ca526a03dc36,

title = "Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9)",

abstract = "The authors would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The Clinical trial number should be “UMIN000001603” at the end of Abstract and in the last sentence of the paragraph heading “Study design and patients” under “Materials and methods” section. Secondly, the Fig. 1 was incorrectly published with the meaningless red font. The corrected figure is given below: (Figure presented.).",

author = "Tadahiko Igarashi and Michinori Ogura and Kuniaki Itoh and Masafumi Taniwaki and Kiyoshi Ando and Yoshiaki Kuroda and Kazuhito Yamamoto and Naokuni Uike and Akihiro Tomita and Hirokazu Nagai and Mitsutoshi Kurosawa and Shigeo Mori and Shigeru Nawano and Takashi Terauchi and Yasuo Ohashi and Kensei Tobinai",

note = "Publisher Copyright: {\textcopyright} 2016, The Japanese Society of Hematology.",

year = "2017",

month = jan,

day = "1",

doi = "10.1007/s12185-016-2155-3",

language = "English",

volume = "105",

pages = "109--110",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer",

number = "1",

}

Igarashi, T, Ogura, M, Itoh, K, Taniwaki, M, Ando, K, Kuroda, Y, Yamamoto, K, Uike, N, Tomita, A, Nagai, H, Kurosawa, M, Mori, S, Nawano, S, Terauchi, T, Ohashi, Y & Tobinai, K 2017, 'Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9)', International Journal of Hematology, vol. 105, no. 1, pp. 109-110. https://doi.org/10.1007/s12185-016-2155-3

Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9). / Igarashi, Tadahiko; Ogura, Michinori; Itoh, Kuniaki et al.
In: International Journal of Hematology, Vol. 105, No. 1, 01.01.2017, p. 109-110.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Erratum to

T2 - Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9)

AU - Igarashi, Tadahiko

AU - Ogura, Michinori

AU - Itoh, Kuniaki

AU - Taniwaki, Masafumi

AU - Ando, Kiyoshi

AU - Kuroda, Yoshiaki

AU - Yamamoto, Kazuhito

AU - Uike, Naokuni

AU - Tomita, Akihiro

AU - Nagai, Hirokazu

AU - Kurosawa, Mitsutoshi

AU - Mori, Shigeo

AU - Nawano, Shigeru

AU - Terauchi, Takashi

AU - Ohashi, Yasuo

AU - Tobinai, Kensei

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The authors would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The Clinical trial number should be “UMIN000001603” at the end of Abstract and in the last sentence of the paragraph heading “Study design and patients” under “Materials and methods” section. Secondly, the Fig. 1 was incorrectly published with the meaningless red font. The corrected figure is given below: (Figure presented.).

AB - The authors would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The Clinical trial number should be “UMIN000001603” at the end of Abstract and in the last sentence of the paragraph heading “Study design and patients” under “Materials and methods” section. Secondly, the Fig. 1 was incorrectly published with the meaningless red font. The corrected figure is given below: (Figure presented.).

UR - http://www.scopus.com/inward/record.url?scp=84997637174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997637174&partnerID=8YFLogxK

U2 - 10.1007/s12185-016-2155-3

DO - 10.1007/s12185-016-2155-3

M3 - Comment/debate

C2 - 27896571

AN - SCOPUS:84997637174

SN - 0925-5710

VL - 105

SP - 109

EP - 110

JO - International Journal of Hematology

JF - International Journal of Hematology

IS - 1

ER -

Igarashi T, Ogura M, Itoh K, Taniwaki M, Ando K, Kuroda Y et al. Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9). International Journal of Hematology. 2017 Jan 1;105(1):109-110. doi: 10.1007/s12185-016-2155-3

Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9)

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this